Patent Number: 6,310,208

Title: Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines

Abstract: Since the compounds in accordance with the invention can bind to serotonin receptors (5HT.sub.2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioral disorders, addiction, obesity, bulimia etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases etc.; cardiovascular disorders such as hypertension, thrombosis, stroke etc.; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Inventors: Bos; Michael (Rheinfelden, CH), Stadler; Heinz (Rheinfelden, CH), Wichmann; Jurgen (Steinen, DE)

Assignee: Hoffmann-La Roche Inc.

International Classification: C07D 221/10 (20060101); C07D 221/00 (20060101); C07D 491/56 (); C07D 221/10 (); C07D 209/62 (); A61K 031/473 (); A61K 031/403 ()

Expiration Date: 10/30/2018